POCT Product Overseas Registration: Can Test Reports Be Reused?

Published: 2026-07-29; Updated: 2026-07-29

Key Summary

Whether POCT product test reports can be reused for overseas registration depends on the target country's regulatory requirements, product risk classification, the issuing laboratory's recognition status, and whether the testing standards are accepted. Companies should first confirm whether the target country is a GHWP member or adopts international standards such as ISO 13485 and IEC 61010, and then determine whether existing NMPA, CE, FDA, or other market reports can be submitted directly. Critical factors include product classification consistency, coverage of local special requirements in technical documentation such as mains voltage, biocompatibility, and performance evaluation, mutual recognition of clinical evidence, and localization of labels and instructions for use. Common risks include expired reports, laboratories not recognized by the target country, and missing test items such as interference testing for specific infectious disease markers.

Companies should compile an inventory of existing reports before the project starts and compare them item by item against the target country's registration guidance. If necessary, supplementary differential testing should be performed, or an overseas authorized representative should be engaged to support evidence conversion. For multi-country registration, using a core report template and management system audits such as MDSAP can reduce duplicate testing, but companies must consider each country's differentiated requirements for quality management systems and post-market surveillance. Overall, test reports can be reused under certain conditions, but systematic assessment and localization adaptation are essential.

Applicable Scenarios and Core Questions

POCT products are widely used in emergency care, primary care, and home self-testing because of their rapid testing and ease of use. After obtaining NMPA registration in China, companies often hope to use existing test reports directly for overseas registration to reduce costs and time. However, different countries have different regulatory systems, technical standards, and clinical requirements for medical devices. Direct reuse may lead to deficiencies or rejection. Core questions include whether laboratory accreditation is mutually recognized, whether testing standards are equivalent, whether product classification is consistent, and whether local clinical evaluation is required.

Companies should first determine whether the target country belongs to GHWP, such as China, Russia, South Korea, and some Southeast Asian countries, or to non-GHWP regions such as the US FDA or EU CE, and identify the product risk class, for example Class II or III in the US and Class A, B, C, or D in the EU.

For example, if a blood glucose POCT product has completed NMPA registration and the test report was issued by a CNAS laboratory, the company must assess whether the report meets ISO 15197 and the EU common specifications when applying for CE marking under the IVDR. Similarly, when applying for FDA 510(k), the report must satisfy CLIA requirements and FDA-recognized consensus standards. Therefore, a gap analysis against the target country's registration guidance is necessary before reuse.

Registration Decision Logic

Step 1: Determine Regulatory Scope

Confirm whether the product falls within the target country's medical device regulatory scope. Different countries define medical devices differently. For example, FDA classifies some POCT products as in vitro diagnostics, while under the EU IVDR all IVDs are regulated. If the product is outside the regulatory scope, registration may not be required, but other market access rules may still apply.

Step 2: Determine Risk Class and Registration Path

Risk class determines the registration path. For example, EU Class A products may be self-declared, while Class D products require notified body review. In the US, Class II products usually require a 510(k) submission, and Class III requires PMA. Report acceptability depends on the path: under self-declaration, the company can decide report validity, but when a notified body or FDA reviews the application, reports must meet recognized standards.

Step 3: Assess Whether Existing Reports Can Be Reused

Key factors include whether the testing laboratory has ISO 17025 accreditation or equivalent local recognition, whether the testing standards are adopted by the target country, such as IEC 61010-1, ISO 13485, and ISO 23640, whether the reports are still within their validity period, typically three to five years, and whether the testing items cover target-country-specific requirements such as transport stability, high temperature and humidity conditions, and verification of different sample types.

Step 4: Confirm Technical Documentation Completeness

Technical documentation should include performance verification, risk assessment, clinical evaluation if applicable, stability studies, and labeling. If existing reports cover only part of the required items, the missing parts must be supplemented. For instance, Southeast Asian countries often require clinical performance data from local populations, while the Middle East may require electrical safety reports adapted to local mains voltage.

Documentation and Evidence

When preparing to reuse test reports, companies should compile the following evidence chain: original reports and the corresponding testing standards, laboratory qualification certificates such as CNAS, DAkkS, or UKAS, descriptions of test methodology, summary of raw data, and deviation explanations if applicable. An authorization letter or technical cooperation agreement from the issuing laboratory may also be required. In addition, the quality management system certificate, ISO 13485 or MDSAP, is fundamental to demonstrate that the production process is controlled.

If clinical evaluation materials such as literature reviews, comparative analysis with equivalent products, or clinical trial reports are available, confirm whether they are accepted by the target country. Labels and instructions for use must be translated into the target language and comply with local requirements, including CE marking, UDI, and LOINC codes where applicable.

In GHWP member countries, such as China, Russia, Brazil, South Korea, and the United Arab Emirates, some mutual recognition agreements for medical device registration can reduce duplicate testing. For example, when using an NMPA report in Russia, the Russian authority may accept certain CNAS laboratory reports, but additional Russian translation and notarization are required. Companies should build a document cross-reference table listing each report against the corresponding regulatory provisions of the target country to facilitate reviewer verification.

Common Errors

• Not verifying laboratory accreditation: Directly using reports from non-recognized laboratories leads to requests for retesting.
• Ignoring standard differences: For example, domestic GB/T standards may not be accepted when the target country requires ISO or ASTM, without a differential assessment.
• Extending report use beyond scope: Reusing reports for other models or different analytes without providing equivalence justification.
• Missing localization evidence: Applying one report to multiple countries without considering local clinical context or epidemiological differences.
• Expired reports: Submitting reports issued more than five years ago without ongoing stability data.
• Unclear agent responsibilities: Failing to appoint a local agent or authorized representative before submission, resulting in rejection.

Preparation Checklist for Companies

• Identify the target country and product risk class.
• Collect an inventory of existing test reports and qualification certificates.
• Create a gap analysis table against the target country's registration guidance.
• Determine whether additional clinical evidence or local testing is needed.
• Ensure the quality management system certificate, ISO 13485 or MDSAP, is valid.
• Prepare translated and locally adapted labels and instructions for use.
• Sign agreements with local agents or authorized representatives.
• Plan post-market maintenance activities, such as vigilance and report updates.
• Assess multi-country registration strategies, such as using MDSAP to coordinate audits.

AIMEILI Regulatory Interpretation and Business Impact

The most common mistake companies make is assuming that domestic registration success is automatically accepted internationally. In reality, NMPA, CE, and FDA requirements for test reports differ significantly. Before starting a project, a systematic gap analysis should be performed to identify reports that can be fully reused, those that require partial supplementation, and those that must be newly generated. In general, basic test reports for electrical safety, biocompatibility, and electromagnetic compatibility have higher reuse rates, while clinical performance verification and local adaptability reports require stronger localization.

Selection of a local agent is critical. The agent not only handles registration responsibilities but also manages change notifications, renewals, and adverse event reporting. Companies should retain control over the certificates and technical files to avoid market access issues if the agent changes. For multi-country registration, a core technical documentation library should be established, using a modular approach to generate country-specific files and reduce the risk of redundant work or deficiencies.

Although GHWP has a trend toward mutual recognition, each country retains independent approval authority. Companies cannot rely on a one-click recognition mechanism. Finally, post-market surveillance data, such as user complaints and performance tracking, affects the ongoing validity of test reports in different countries and should be managed proactively.

Common Follow-up Questions

Can an NMPA report be used for EU CE registration?

This depends on the specific project. Under the EU IVDR, notified bodies accept data from laboratories that comply with ISO 17025, and CNAS laboratories in China are generally accepted. However, the report must cover IVDR-specific requirements such as clinical performance evaluation and analytical sensitivity, and an EU authorized representative must provide the required declaration. Early communication with the notified body is strongly recommended.

Does FDA accept CE reports?

FDA does not directly accept CE reports. However, if the report was issued by an FDA-recognized laboratory and follows FDA-recognized consensus standards such as CLSI guidelines, it may be used as supporting evidence. FDA-specific requirements, such as 21 CFR Part 11 electronic records, must often be supplemented. For a 510(k) submission, complete performance data are required, and even CE reports must be converted into the appropriate format.

Can companies perform only one test report for multiple countries?

It is possible to try using internationally accepted standards such as ISO, IEC, and ICH, and ensuring laboratory accreditation is recognized by multiple countries. In practice, however, local differences in mains voltage, climate, and population often require a small number of additional localization tests. A core report plus country-specific supplementary testing model is recommended.